Method for determination of (-102C>T) single nucleotide polymorphism in the human manganese superoxide dismutase promoter

BMC Genetics

David W Hein⁵  Nathaniel Rothman²  Jolanta Lissowska⁴  Benjamin D Martini³  Qing Lan²  Mark A Doll³  Kalista Hughes¹  Robert CG Martin⁵ 

[1] Departments of Surgery, University of Louisville School of Medicine, Louisville, KY, USA;Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA;Pharmacology & Toxicology, University of Louisville School of Medicine, Louisville, KY, USA;Division of Cancer Epidemiology and Prevention, Cancer Center and M. Slodowska-Curie Institute of Oncology, Warsaw, Poland;James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, USA

关键词: genotyping;    Human manganese superoxide dismutase;    MnSOD;   

Others  :  1143737
DOI  :  10.1186/1471-2156-5-33

 received in 2004-04-14, accepted in 2004-12-14,  发布年份 2004

【 摘 要 】

Background

Manganese superoxide dismutase (MnSOD) plays a critical role in the detoxification of mitochondrial reactive oxygen species constituting a major cellular defense mechanism against agents that induce oxidative stress. The MnSOD promoter contains an activator protein-2 (AP-2) binding site that modifies transcription of MnSOD. Mutations have been identified in the proximal region of the promoter in human tumor cell lines. One of these mutations (-102C>T) has been shown to change the binding pattern of AP-2 leading to a reduction in transcriptional activity. The aim of our study was to develop a method to identify and determine the frequency of this (-102C>T) polymorphism in human tissues.

Results

A new TaqMan allelic discrimination genotype method was successfully applied to genomic DNA samples derived from blood, buccal swabs, snap frozen tissue and paraffin blocks. The polymorphism was shown to be in Hardy-Weinberg Equilibrium in an evaluation of 130 Caucasians from Warsaw, Poland: 44 (33.8%) were heterozygous and 6 (4.6%) were homozygous for -102T.

Conclusion

This report represents the first description of the MnSOD -102C>T polymorphism in human subjects by a novel Taqman allelic discrimination assay. This method should enable molecular epidemiological studies to evaluate possible associations of this polymorphism with malignancies and other diseases related to reactive oxygen species.

【 授权许可】

   
2004 Martin et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]St Clair D, Wan XS, Kuroda M, Vichitbandha S, Tsuchida E, Urano M: Suppresion of tumor metastasis by manganese superoxide dismutase is associated with reduced tumorigenicity and elevated fibronectin. Oncol Rep 1997, 4:753-757.
• [2]Ku HH, Brunk UT, Sohal RS: Relationship between mitochondrial superoxide and hydrogen peroxide production and longevity of mammalian species. Free Radic Biol Med 1993, 15:621-627.
• [3]Halliwell B: The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 1993, 23(Suppl 1):118-126.
• [4]Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RH Jr, Beal MF: Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997, 69:2064-2074.
• [5]Fahn S, Cohen G: The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992, 32:804-812.
• [6]McCord JM, Fridovich I: Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969, 244:6049-6055.
• [7]Marklund SL: Human copper-containing superoxide dismutase of high molecular weight. Proc Natl Acad Sci U S A 1982, 79:7634-7638.
• [8]Weisiger RA, Fridovich I: Mitochondrial superoxide simutase. Site of synthesis and intramitochondrial localization. J Biol Chem 1973, 248:4793-4796.
• [9]Zhao Y, Xue Y, Oberley TD, Kiningham KK, Lin SM, Yen HC, Majima H, Hines J, St Clair D: Overexpression of manganese superoxide dismutase suppresses tumor formation by modulation of activator protein-1 signaling in a multistage skin carcinogenesis model. Cancer Res 2001, 61:6082-6088.
• [10]Zhao Y, Oberley TD, Chaiswing L, Lin SM, Epstein CJ, Huang TT, StClair D: Manganese superoxide dismutase deficiency enhances cell turnover via tumor promoter-induced alterations in AP-1 and p53-mediated pathways in a skin cancer model. Oncogene 2002, 21:3836-3846.
• [11]St Clair DK, Wan XS, Kuroda M, Vichitbandha S, Tsuchida E, Urano M: Suppression of tumor metastasis by maganese superoxide dismutase is associated with reduced tumorigenicity and elevated fibronectin. Oncol Rep 1997, 4:753-757.
• [12]Hernandez-Saavedra D, McCord JM: Paradoxical effects of thiol reagents on Jurkat cells and a new thiol-sensitive mutant form of human mitochondrial superoxide dismutase. Cancer Res 2003, 63:159-163.
• [13]Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura MP, Berger C, Chan PH: Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 1995, 11:376-381.
• [14]Wispe JR, Warner BB, Clark JC, Dey CR, Neuman J, Glasser SW, Crapo JD, Chang LY, Whitsett JA: Human Mn-superoxide dismutase in pulmonary epithelial cells of transgenic mice confers protection from oxygen injury. J Biol Chem 1992, 267:23937-23941.
• [15]Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK: The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 1996, 98:1253-1260.
• [16]Yen HC, Oberley TD, Gairola CG, Szweda LI, St Clair DK: Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice. Arch Biochem Biophys 1999, 362:59-66.
• [17]Ambrosone CB, Freudenheim JL, Thompson PA, Bowman E, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, Shields PG: Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res 1999, 59:602-606.
• [18]Mitrunen K, Sillanpaa P, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Uusitupa M, Hirvonen A: Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis 2001, 22:827-829.
• [19]Wang LI, Miller DP, Sai Y, Liu G, Su L, Wain JC, Lynch TJ, Christiani DC: Manganese superoxide dismutase alanine-to-valine polymorphism at codon 16 and lung cancer risk. J Natl Cancer Inst 2001, 93:1818-1821.
• [20]Hiroi S, Harada H, Nishi H, Satoh M, Nagai R, Kimura A: Polymorphisms in the SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in Japanese. Biochem Biophys Res Commun 1999, 261:332-339.
• [21]Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y: Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochem Biophys Res Commun 1996, 226:561-565.
• [22]Oberley LW, Buettner GR: Role of superoxide dismutase in cancer: a review. Cancer Res 1979, 39:1141-1149.
• [23]St Clair DK, Holland JC: Complementary DNA encoding human colon cancer manganese superoxide dismutase and the expression of its gene in human cells. Cancer Res 1991, 51:939-943.
• [24]Wan XS, Devalaraja MN, St Clair DK: Molecular structure and organization of the human manganese superoxide dismutase gene. DNA Cell Biol 1994, 13:1127-1136.
• [25]Xu Y, Krishnan A, Wan XS, Majima H, Yeh CC, Ludewig G, Kasarskis EJ, St Clair DK: Mutations in the promoter reveal a cause for the reduced expression of the human manganese superoxide dismutase gene in cancer cells. Oncogene 1999, 18:93-102.
• [26]Martin RCG, Hughes KH, Doll MA, Rothman N, Hein DW: Homo sapiens manganese superoxide dismutase gene, 5' flanking sequence. Genbank AY397775 2003. Ref Type: Abstract
• [27]Carlioz A, Touati D: Isolation of superoxide dismutase mutants in Escherichia coli: is superoxide dismutase necessary for aerobic life? EMBO J 1986, 5:623-630.
• [28]Farr SB, D'Ari R, Touati D: Oxygen-dependent mutagenesis in Escherichia coli lacking superoxide dismutase. Proc Natl Acad Sci U S A 1986, 83:8268-8272.
• [29]Xu Y, Krishnan A, Wan XS, Majima H, Yeh CC, Ludewig G, Kasarskis EJ, St Clair DK: Mutations in the promoter reveal a cause for the reduced expression of the human manganese superoxide dismutase gene in cancer cells. Oncogene 1999, 18:93-102.
• [30]Xu Y, Krishnan A, Wan XS, Majima H, Yeh CC, Ludewig G, Kasarskis EJ, St Clair DK: Mutations in the promoter reveal a cause for the reduced expression of the human manganese superoxide dismutase gene in cancer cells. Oncogene 1999, 18:93-102.
• [31]Xu Y, Krishnan A, Wan XS, Majima H, Yeh CC, Ludewig G, Kasarskis EJ, St Clair DK: Mutations in the promoter reveal a cause for the reduced expression of the human manganese superoxide dismutase gene in cancer cells. Oncogene 1999, 18:93-102.
• [32]Chow WH, Swanson CA, Lissowska J, Groves FD, Sobin LH, Nasierowska-Guttmejer A, Radziszewski J, Regula J, Hsing AW, Jagannatha S, Zatonski W, Blot WJ: Risk of stomach cancer in relation to consumption of cigarettes, alcohol, tea and coffee in Warsaw, Poland. Int J Cancer 1999, 81:871-876.
• [33]Doll MA, Hein DW: Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes. Anal Biochem 2001, 288:106-108.
• [34]Doll MA, Hein DW: Rapid genotype method to distinguish frequent and/or functional polymorphisms in human N-acetyltransferase-1. Anal Biochem 2002, 301:328-332.